• Revance to get $25M upfront- milestone payments upon achievement of additional clinical- regulatory and sales targets- plus sales royalties in all relevant markets and will be finalized till Apr 30- 2020
• In Feb 2018- Revance and Mylan signed global collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX (onabotulinumtoxinA)
• BOTOX is a neurotoxin therapy injected in the muscles to treat increased muscle stiffness & eye muscle problems (strabismus) or abnormal spasm of the eyelids (blepharospasm)

Click here to read full press release/ article | Ref: Seeking Alpha | Image: Behance